Cancer cell growth inhibition by aroylhydrazone derivatives. Issue 1 (1st January 2019)

• Record Type: Journal Article
• Authors: Iliev, Ivan; Kontrec, Darko; Detcheva, Roumiana; Georgieva, Maya; Balacheva, Anelia; Galić, Nives; Pajpanova, Tamara
• Is Part Of: Biotechnology, biotechnological equipment. Volume 33:Issue 1(2019)
• Page Start: 756
• Page End: 763
• Publication Date: 2019-01-01
• Subjects: Aroylhydrazones -- nicotinic acid hydrazide -- isonicotinic acid hydrazide -- antiproliferative activity; Biotechnology -- Periodicals; Biotechnology -- Periodicals; Biotechnology -- instrumentation -- Periodicals; Periodicals; 660.605
• DOI: 10.1080/13102818.2019.1608302
• Languages: English
• ISSNs: 1310-2818

Abstract

Abstract: Hydrazones have versatile properties that make them promising for a range of possible applications. In this study, we examined a library of 17 aroylhydrazones derived from nicotinic acid hydrazide (1-12 ) and isonicotinic acid hydrazide (A-E ) created by us for their biological activity. The antiproliferative activity of the compounds was investigated on non-tumour MCF-10A cells and cancer cell lines, MCF-7 and MDA-MB-231. Four compounds were selected as most active in cell growth inhibition of the tumour cell lines. These compounds, 5, 11, C and E, were tested on four additional cell lines: non-tumour BJ and cancer cell lines, HeLa, HepG2 and HT-29. Compounds 5 and E exhibited the highest selectivity index on cancer cell lines MDA-MB-231, HeLa and HepG2. High selectivity to MCF-7 cells was demonstrated with compound 5 . Compound C was very selective to HepG2 cells as well as to MDA-MB-231 but to a lesser degree. Compound 11 showed selectivity against MDA-MB-231. The obtained results allow assessing the structure–activity relationship of the compounds and provide insight into the further development of this group of aroylhydrazones as more potent and selective anti-neoplastic agents.